ALX Oncology Holdings Inc. (NASDAQ:ALXO) Shares Sold by Federated Hermes Inc.

Federated Hermes Inc. trimmed its holdings in ALX Oncology Holdings Inc. (NASDAQ:ALXO - Free Report) by 21.8% in the 4th quarter, according to its most recent disclosure with the SEC. The firm owned 196,536 shares of the company's stock after selling 54,824 shares during the period. Federated Hermes Inc. owned approximately 0.39% of ALX Oncology worth $2,926,000 at the end of the most recent quarter.

Several other hedge funds also recently added to or reduced their stakes in ALXO. Zurcher Kantonalbank Zurich Cantonalbank purchased a new position in shares of ALX Oncology during the fourth quarter worth $28,000. SG Americas Securities LLC purchased a new position in shares of ALX Oncology during the third quarter worth $48,000. Forefront Analytics LLC purchased a new position in shares of ALX Oncology during the third quarter worth $66,000. China Universal Asset Management Co. Ltd. boosted its position in shares of ALX Oncology by 445.6% during the fourth quarter. China Universal Asset Management Co. Ltd. now owns 5,762 shares of the company's stock worth $86,000 after buying an additional 4,706 shares during the period. Finally, J.P. Morgan Private Wealth Advisors LLC purchased a new position in shares of ALX Oncology during the third quarter worth $96,000. 97.97% of the stock is currently owned by hedge funds and other institutional investors.

Insider Buying and Selling

In related news, insider Jaume Pons sold 50,000 shares of the firm's stock in a transaction dated Tuesday, April 16th. The stock was sold at an average price of $14.20, for a total transaction of $710,000.00. Following the transaction, the insider now owns 604,205 shares of the company's stock, valued at $8,579,711. The transaction was disclosed in a filing with the SEC, which is accessible through this link. In related news, insider Jaume Pons sold 50,000 shares of the firm's stock in a transaction dated Tuesday, April 16th. The stock was sold at an average price of $14.20, for a total transaction of $710,000.00. Following the transaction, the insider now owns 604,205 shares of the company's stock, valued at $8,579,711. The transaction was disclosed in a filing with the SEC, which is accessible through this link. Also, CEO Jason Lettmann purchased 4,400 shares of the stock in a transaction that occurred on Thursday, March 14th. The shares were bought at an average cost of $11.31 per share, for a total transaction of $49,764.00. Following the acquisition, the chief executive officer now owns 171,620 shares of the company's stock, valued at $1,941,022.20. The disclosure for this purchase can be found here. Corporate insiders own 50.30% of the company's stock.

Wall Street Analysts Forecast Growth

ALXO has been the subject of several research analyst reports. Cantor Fitzgerald restated an "overweight" rating on shares of ALX Oncology in a research report on Friday, April 12th. Stifel Nicolaus reiterated a "hold" rating and issued a $14.00 price objective (up from $10.00) on shares of ALX Oncology in a research note on Friday, March 8th. Finally, HC Wainwright restated a "buy" rating and issued a $20.00 price target on shares of ALX Oncology in a research note on Wednesday, April 10th. One research analyst has rated the stock with a hold rating and five have assigned a buy rating to the stock. According to MarketBeat.com, the company currently has a consensus rating of "Moderate Buy" and a consensus price target of $18.83.

ALX Oncology Stock Performance

Shares of ALXO stock traded down $0.01 during mid-day trading on Friday, hitting $16.86. 466,719 shares of the stock were exchanged, compared to its average volume of 595,653. The stock's fifty day simple moving average is $13.63 and its two-hundred day simple moving average is $12.31. The stock has a market capitalization of $843 million, a price-to-earnings ratio of -4.50 and a beta of 1.58. ALX Oncology Holdings Inc. has a 12-month low of $3.94 and a 12-month high of $17.42. The company has a debt-to-equity ratio of 0.05, a quick ratio of 5.24 and a current ratio of 5.24.

ALX Oncology (NASDAQ:ALXO - Get Free Report) last issued its quarterly earnings data on Thursday, March 7th. The company reported ($0.93) earnings per share (EPS) for the quarter, missing the consensus estimate of ($0.84) by ($0.09). On average, analysts forecast that ALX Oncology Holdings Inc. will post -3.33 EPS for the current year.

About ALX Oncology

ALX Oncology Holdings Inc, a clinical-stage immuno-oncology company, focuses on developing therapies for cancer patients in the United States. The company's lead product candidate is Evorpacept, a CD47 blocking therapeutic biologic in development as a combination therapy with other anti-cancer agents, including ASPEN-06, under Phase 2 clinical study for treating Gastric/GEJ cancer; ASPEN-07, under Phase 1 clinical study for treating urothelial cancer; and ASPEN-03 and ASPEN-04, both under Phase 2 clinical study for treating head and neck squamous cell carcinoma.